Caxton Associates LLP Takes $389,000 Position in Avanos Medical, Inc. $AVNS

Key Points

• Caxton Associates LLP has acquired 27,116 shares of Avanos Medical, valued at approximately $389,000, indicating a growing interest from institutional investors.
• Avanos Medical's quarterly earnings missed estimates with an EPS of $0.17, lower than the expected $0.18, while revenue for the quarter was $175 million, surpassing expectations.
• Stock analysts have issued mixed ratings for Avanos Medical, with Wall Street Zen downgrading the stock from "strong-buy" to "buy," and Zacks Research upgrading it to a "hold" rating.

Caxton Associates LLP bought a new position in shares of Avanos Medical, Inc. (NYSE:AVNS - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 27,116 shares of the company's stock, valued at approximately $389,000. Caxton Associates LLP owned about 0.06% of Avanos Medical at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. GAMMA Investing LLC lifted its stake in shares of Avanos Medical by 2,381.6% during the first quarter. GAMMA Investing LLC now owns 17,024 shares of the company's stock valued at $244,000 after buying an additional 16,338 shares during the period. Bank of America Corp DE boosted its stake in shares of Avanos Medical by 2.5% in the fourth quarter. Bank of America Corp DE now owns 63,672 shares of the company's stock valued at $1,014,000 after purchasing an additional 1,537 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Avanos Medical by 2.6% in the first quarter. Principal Financial Group Inc. now owns 244,063 shares of the company's stock valued at $3,497,000 after purchasing an additional 6,269 shares during the period. T. Rowe Price Investment Management Inc. boosted its stake in shares of Avanos Medical by 24.8% in the first quarter. T. Rowe Price Investment Management Inc. now owns 3,757,576 shares of the company's stock valued at $53,847,000 after purchasing an additional 746,264 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Avanos Medical in the first quarter valued at $344,000. Institutional investors and hedge funds own 95.17% of the company's stock.

Avanos Medical Stock Performance

AVNS stock traded up $0.21 on Thursday, reaching $12.07. 60,738 shares of the company were exchanged, compared to its average volume of 539,119. Avanos Medical, Inc. has a 12 month low of $9.30 and a 12 month high of $25.36. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.64 and a quick ratio of 1.58. The stock's fifty day moving average price is $11.62 and its 200 day moving average price is $12.53. The firm has a market capitalization of $559.82 million, a PE ratio of -1.20 and a beta of 1.12.

Avanos Medical (NYSE:AVNS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $175.00 million for the quarter, compared to analyst estimates of $165.50 million. Avanos Medical had a positive return on equity of 6.16% and a negative net margin of 66.89%.During the same quarter in the prior year, the firm earned $0.34 EPS. Avanos Medical has set its FY 2025 guidance at 0.750-0.950 EPS. On average, research analysts anticipate that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Wall Street Zen cut shares of Avanos Medical from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Zacks Research upgraded shares of Avanos Medical to a "hold" rating in a research report on Tuesday, August 12th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, Avanos Medical currently has an average rating of "Hold".

Insider Transactions at Avanos Medical

In other news, Director Gary Blackford acquired 40,000 shares of the company's stock in a transaction on Wednesday, August 13th. The stock was purchased at an average cost of $10.99 per share, with a total value of $439,600.00. Following the acquisition, the director owned 40,000 shares of the company's stock, valued at $439,600. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.64% of the stock is currently owned by company insiders.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.